Hologic acquires developer of fibroid treatment

Aug. 28, 2020

Hologic has acquired Acessa Health, a privately held developer of minimally invasive treatment for fibroids, for approximately $80 million in cash plus contingent payments based on future revenue growth, according to a news report from Hologic.

Acessa Health markets the Acessa ProVu system, a fully integrated laparoscopic system that combines radiofrequency ablation with advanced intra-abdominal ultrasound visualization and guidance mapping, enabling physicians to treat women with symptomatic, benign uterine fibroids.

According to Hologic, studies have shown that the Acessa ProVu system is a safe and minimally invasive alternative to hysterectomy and myomectomy. The system is indicated for treatment of benign uterine fibroids and is designed to detect more fibroids as compared to current imaging modalities. Radiofrequency treatment of fibroids is supported by clinical data demonstrating less blood loss and faster recovery times as compared to standard treatments currently available.

Uterine fibroids – also referred to as uterine leiomyomas or myomas – are common, benign tumors that grow in or on the uterus. They can cause heavy menstrual bleeding, pain, frequent urination, and other symptoms that lead to missed work time and limit normal daily activities.

The incidence of uterine fibroids among women is between 50 percent and 60 percent, increasing to approximately 70 percent by age 50. African American women are two to three times more likely to be affected by fibroids, particularly at an earlier age, compared to Caucasian or Asian women, and fibroids are a significant cause of morbidity in this population, Hologic said, citing research studies.

Visit Hologic for more news